Spectroscopic study on volasertib: Highly stable complexes with albumin and encapsulation into alginate/montmorillonite bionanocomposites

In the present work, we study different physicochemical properties related to LADME processes of volasertib, a Polo-like kinase 1 inhibitor in advanced clinical trials. Firstly, the protonation equilibria, the extent of ionization at the physiological pH and pKa values of this drug are studied combi...

Full description

Bibliographic Details
Authors: Fernández Sainz, Jesús, Herrera Ochoa, Diego, Pacheco Liñán, Pedro J., Darder, Margarita, Albaladejo Pérez, José, Bravo Pérez, Iván, Garzón Ruiz, Andrés
Format: article
Publication Date:2024
Country:España
Institution:Universidad de Castilla-La Mancha
Repository:RUIdeRA. Repositorio Institucional de la UCLM
OAI Identifier:oai:ruidera.uclm.es:10578/40305
Online Access:https://www.sciencedirect.com/science/article/pii/S1386142524009892?via%3Dihub
https://hdl.handle.net/10578/40305
Access Level:Open access
Keyword:Alginate, montmorillonite, bionanocomposite
Fluorescence spectroscopy in proteins
Human serum albumin
Volasertib
Description
Summary:In the present work, we study different physicochemical properties related to LADME processes of volasertib, a Polo-like kinase 1 inhibitor in advanced clinical trials. Firstly, the protonation equilibria, the extent of ionization at the physiological pH and pKa values of this drug are studied combining spectroscopic techniques and computational calculations. Secondly, the binding process of volasertib to the human serum albumin (HSA) protein is analyzed by fluorescence spectroscopy. We report a high binding constant to HSA (Ka = 4.10 × 106 M-1) and their pharmacokinetic implications are discussed accordingly. The negative enthalpy and entropy (?H0 = -54.49 kJ/mol; ?S0 = -58.90 J K-1 mol-1) determined for the binding process suggests the implication of hydrogen bonds and van der Waals interactions in the formation of the HSA-volasertib complex. Additionally, volasertib is encapsulated in an alginate/montmorillonite bionanocomposite as a proof of concept for an oral delivery nanocarrier. The physical properties of that nanocomposite as well as volasertib delivery kinetics are analyzed.